nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.14	0.404	CbGbCtD
Thalidomide—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.113	0.326	CbGbCtD
Thalidomide—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0941	0.271	CbGbCtD
Thalidomide—Hodgkin's disease lymphocyte depletion type stage unspecified—Cyclosporine—focal segmental glomerulosclerosis	0.0253	0.0644	CcSEcCtD
Thalidomide—Gingival disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0253	0.0644	CcSEcCtD
Thalidomide—Hodgkin's disease lymphocyte predominance type stage unspecified—Cyclosporine—focal segmental glomerulosclerosis	0.0253	0.0644	CcSEcCtD
Thalidomide—Hodgkin's disease—Cyclosporine—focal segmental glomerulosclerosis	0.0253	0.0644	CcSEcCtD
Thalidomide—Posterior reversible encephalopathy syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.0145	0.037	CcSEcCtD
Thalidomide—Consciousness abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.0138	0.035	CcSEcCtD
Thalidomide—PTGS2—nephron—focal segmental glomerulosclerosis	0.00896	0.131	CbGeAlD
Thalidomide—NFKB1—kidney—focal segmental glomerulosclerosis	0.00745	0.109	CbGeAlD
Thalidomide—Polyneuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00733	0.0186	CcSEcCtD
Thalidomide—NFKB1—cortex of kidney—focal segmental glomerulosclerosis	0.00725	0.106	CbGeAlD
Thalidomide—CRBN—nephron tubule—focal segmental glomerulosclerosis	0.0071	0.104	CbGeAlD
Thalidomide—CRBN—cortex of kidney—focal segmental glomerulosclerosis	0.00608	0.0888	CbGeAlD
Thalidomide—FGFR2—kidney—focal segmental glomerulosclerosis	0.00559	0.0817	CbGeAlD
Thalidomide—Altered state of consciousness—Cyclosporine—focal segmental glomerulosclerosis	0.00517	0.0132	CcSEcCtD
Thalidomide—PTGS1—endothelium—focal segmental glomerulosclerosis	0.00442	0.0645	CbGeAlD
Thalidomide—PTGS2—endothelium—focal segmental glomerulosclerosis	0.00422	0.0617	CbGeAlD
Thalidomide—Gastric ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00411	0.0105	CcSEcCtD
Thalidomide—Serum creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00388	0.00987	CcSEcCtD
Thalidomide—Psoriasis—Cyclosporine—focal segmental glomerulosclerosis	0.0038	0.00966	CcSEcCtD
Thalidomide—Hypomagnesaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00376	0.00956	CcSEcCtD
Thalidomide—Tooth disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00368	0.00937	CcSEcCtD
Thalidomide—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00368	0.00937	CcSEcCtD
Thalidomide—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0035	0.00891	CcSEcCtD
Thalidomide—Burning sensation—Cyclosporine—focal segmental glomerulosclerosis	0.00344	0.00874	CcSEcCtD
Thalidomide—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.00337	0.00858	CcSEcCtD
Thalidomide—Thrombosis—Cyclosporine—focal segmental glomerulosclerosis	0.00337	0.00858	CcSEcCtD
Thalidomide—Hyperlipidaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00331	0.00843	CcSEcCtD
Thalidomide—Cholestasis—Cyclosporine—focal segmental glomerulosclerosis	0.00314	0.008	CcSEcCtD
Thalidomide—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00307	0.0078	CcSEcCtD
Thalidomide—Hyperaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00304	0.00774	CcSEcCtD
Thalidomide—Tingling sensation—Cyclosporine—focal segmental glomerulosclerosis	0.00297	0.00756	CcSEcCtD
Thalidomide—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.00284	0.00722	CcSEcCtD
Thalidomide—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00272	0.00691	CcSEcCtD
Thalidomide—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00266	0.00677	CcSEcCtD
Thalidomide—Viral infection—Cyclosporine—focal segmental glomerulosclerosis	0.00264	0.00672	CcSEcCtD
Thalidomide—Arthropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00263	0.00668	CcSEcCtD
Thalidomide—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00263	0.00668	CcSEcCtD
Thalidomide—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00263	0.00668	CcSEcCtD
Thalidomide—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00259	0.00659	CcSEcCtD
Thalidomide—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00257	0.00655	CcSEcCtD
Thalidomide—Hearing impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00251	0.00638	CcSEcCtD
Thalidomide—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00251	0.00638	CcSEcCtD
Thalidomide—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00243	0.00619	CcSEcCtD
Thalidomide—Hepatocellular injury—Cyclosporine—focal segmental glomerulosclerosis	0.00239	0.00607	CcSEcCtD
Thalidomide—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.00235	0.00597	CcSEcCtD
Thalidomide—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00235	0.00597	CcSEcCtD
Thalidomide—Candida infection—Cyclosporine—focal segmental glomerulosclerosis	0.00228	0.0058	CcSEcCtD
Thalidomide—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.00225	0.00573	CcSEcCtD
Thalidomide—CYP3A5—nephron tubule—focal segmental glomerulosclerosis	0.00225	0.0329	CbGeAlD
Thalidomide—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00224	0.0057	CcSEcCtD
Thalidomide—Cramps of lower extremities—Cyclosporine—focal segmental glomerulosclerosis	0.00219	0.00558	CcSEcCtD
Thalidomide—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.00218	0.00555	CcSEcCtD
Thalidomide—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.00214	0.00543	CcSEcCtD
Thalidomide—CYP2E1—nephron tubule—focal segmental glomerulosclerosis	0.0021	0.0307	CbGeAlD
Thalidomide—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.00527	CcSEcCtD
Thalidomide—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.00527	CcSEcCtD
Thalidomide—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00203	0.00517	CcSEcCtD
Thalidomide—CYP1A1—kidney—focal segmental glomerulosclerosis	0.00202	0.0296	CbGeAlD
Thalidomide—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00199	0.00507	CcSEcCtD
Thalidomide—CYP3A5—kidney—focal segmental glomerulosclerosis	0.00198	0.0289	CbGeAlD
Thalidomide—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00196	0.00497	CcSEcCtD
Thalidomide—Vascular purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00194	0.00493	CcSEcCtD
Thalidomide—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.00194	0.00493	CcSEcCtD
Thalidomide—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00193	0.00491	CcSEcCtD
Thalidomide—CYP3A5—cortex of kidney—focal segmental glomerulosclerosis	0.00193	0.0282	CbGeAlD
Thalidomide—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.00488	CcSEcCtD
Thalidomide—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.00189	0.0048	CcSEcCtD
Thalidomide—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00187	0.00475	CcSEcCtD
Thalidomide—CYP2E1—kidney—focal segmental glomerulosclerosis	0.00185	0.027	CbGeAlD
Thalidomide—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00184	0.00469	CcSEcCtD
Thalidomide—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00183	0.00465	CcSEcCtD
Thalidomide—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00461	CcSEcCtD
Thalidomide—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.00457	CcSEcCtD
Thalidomide—CYP2E1—cortex of kidney—focal segmental glomerulosclerosis	0.0018	0.0263	CbGeAlD
Thalidomide—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00454	CcSEcCtD
Thalidomide—PTGS1—kidney—focal segmental glomerulosclerosis	0.00178	0.026	CbGeAlD
Thalidomide—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00452	CcSEcCtD
Thalidomide—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.00452	CcSEcCtD
Thalidomide—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00177	0.0045	CcSEcCtD
Thalidomide—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00173	0.00441	CcSEcCtD
Thalidomide—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.00437	CcSEcCtD
Thalidomide—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.00434	CcSEcCtD
Thalidomide—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.00434	CcSEcCtD
Thalidomide—PTGS2—kidney—focal segmental glomerulosclerosis	0.0017	0.0248	CbGeAlD
Thalidomide—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00418	CcSEcCtD
Thalidomide—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.00413	CcSEcCtD
Thalidomide—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00159	0.00404	CcSEcCtD
Thalidomide—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00157	0.00398	CcSEcCtD
Thalidomide—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.00397	CcSEcCtD
Thalidomide—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.00389	CcSEcCtD
Thalidomide—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00151	0.00384	CcSEcCtD
Thalidomide—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.0015	0.00381	CcSEcCtD
Thalidomide—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.00375	CcSEcCtD
Thalidomide—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.00374	CcSEcCtD
Thalidomide—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00366	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.00354	CcSEcCtD
Thalidomide—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00138	0.00352	CcSEcCtD
Thalidomide—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00136	0.00347	CcSEcCtD
Thalidomide—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00136	0.00345	CcSEcCtD
Thalidomide—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.00344	CcSEcCtD
Thalidomide—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.00342	CcSEcCtD
Thalidomide—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.0034	CcSEcCtD
Thalidomide—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.0034	CcSEcCtD
Thalidomide—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.00339	CcSEcCtD
Thalidomide—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00132	0.00335	CcSEcCtD
Thalidomide—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.00334	CcSEcCtD
Thalidomide—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.00333	CcSEcCtD
Thalidomide—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.00333	CcSEcCtD
Thalidomide—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.00331	CcSEcCtD
Thalidomide—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.0033	CcSEcCtD
Thalidomide—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00324	CcSEcCtD
Thalidomide—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.0032	CcSEcCtD
Thalidomide—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00319	CcSEcCtD
Thalidomide—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.00306	CcSEcCtD
Thalidomide—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.00305	CcSEcCtD
Thalidomide—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00304	CcSEcCtD
Thalidomide—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00303	CcSEcCtD
Thalidomide—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00301	CcSEcCtD
Thalidomide—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00299	CcSEcCtD
Thalidomide—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.00294	CcSEcCtD
Thalidomide—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.00284	CcSEcCtD
Thalidomide—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.00277	CcSEcCtD
Thalidomide—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.00275	CcSEcCtD
Thalidomide—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.00274	CcSEcCtD
Thalidomide—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00272	CcSEcCtD
Thalidomide—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00106	0.0027	CcSEcCtD
Thalidomide—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.00267	CcSEcCtD
Thalidomide—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00104	0.00266	CcSEcCtD
Thalidomide—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.00262	CcSEcCtD
Thalidomide—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.00261	CcSEcCtD
Thalidomide—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00102	0.0026	CcSEcCtD
Thalidomide—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.00258	CcSEcCtD
Thalidomide—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.001	0.00255	CcSEcCtD
Thalidomide—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000984	0.0025	CcSEcCtD
Thalidomide—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000978	0.00249	CcSEcCtD
Thalidomide—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000968	0.00246	CcSEcCtD
Thalidomide—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000965	0.00245	CcSEcCtD
Thalidomide—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.000959	0.00244	CcSEcCtD
Thalidomide—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000954	0.00243	CcSEcCtD
Thalidomide—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000941	0.00239	CcSEcCtD
Thalidomide—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000938	0.00239	CcSEcCtD
Thalidomide—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000934	0.00238	CcSEcCtD
Thalidomide—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000911	0.00232	CcSEcCtD
Thalidomide—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000904	0.0023	CcSEcCtD
Thalidomide—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000901	0.00229	CcSEcCtD
Thalidomide—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000889	0.00226	CcSEcCtD
Thalidomide—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000889	0.00226	CcSEcCtD
Thalidomide—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000889	0.00226	CcSEcCtD
Thalidomide—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000885	0.00225	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000882	0.00225	CcSEcCtD
Thalidomide—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000878	0.00223	CcSEcCtD
Thalidomide—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000869	0.00221	CcSEcCtD
Thalidomide—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000859	0.00219	CcSEcCtD
Thalidomide—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000852	0.00217	CcSEcCtD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—FN1—focal segmental glomerulosclerosis	0.000851	0.00446	CbGpPWpGaD
Thalidomide—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000846	0.00215	CcSEcCtD
Thalidomide—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000835	0.00213	CcSEcCtD
Thalidomide—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000834	0.00212	CcSEcCtD
Thalidomide—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000827	0.0021	CcSEcCtD
Thalidomide—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000823	0.0021	CcSEcCtD
Thalidomide—NFKB1—TWEAK Signaling Pathway—MMP9—focal segmental glomerulosclerosis	0.000819	0.00429	CbGpPWpGaD
Thalidomide—TNF—Matrix Metalloproteinases—MMP9—focal segmental glomerulosclerosis	0.000816	0.00428	CbGpPWpGaD
Thalidomide—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000812	0.00207	CcSEcCtD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—AGT—focal segmental glomerulosclerosis	0.000798	0.00418	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—MMP2—focal segmental glomerulosclerosis	0.000778	0.00407	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000776	0.00197	CcSEcCtD
Thalidomide—TNF—amb2 Integrin signaling—MMP9—focal segmental glomerulosclerosis	0.000775	0.00406	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.000771	0.00404	CbGpPWpGaD
Thalidomide—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00077	0.00196	CcSEcCtD
Thalidomide—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000765	0.00195	CcSEcCtD
Thalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—LPL—focal segmental glomerulosclerosis	0.000762	0.00399	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.000761	0.00399	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—GNAQ—focal segmental glomerulosclerosis	0.00076	0.00398	CbGpPWpGaD
Thalidomide—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000759	0.00193	CcSEcCtD
Thalidomide—NFKB1—AGE/RAGE pathway—MMP2—focal segmental glomerulosclerosis	0.000759	0.00398	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—AGT—focal segmental glomerulosclerosis	0.000758	0.00397	CbGpPWpGaD
Thalidomide—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000757	0.00193	CcSEcCtD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—SPP1—focal segmental glomerulosclerosis	0.000757	0.00397	CbGpPWpGaD
Thalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—focal segmental glomerulosclerosis	0.000755	0.00395	CbGpPWpGaD
Thalidomide—TNF—IL27-mediated signaling events—TGFB1—focal segmental glomerulosclerosis	0.000755	0.00395	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000754	0.00395	CbGpPWpGaD
Thalidomide—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00075	0.00191	CcSEcCtD
Thalidomide—TNF—Alzheimers Disease—LPL—focal segmental glomerulosclerosis	0.000747	0.00391	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—SERPINE1—focal segmental glomerulosclerosis	0.000745	0.0039	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—ALB—focal segmental glomerulosclerosis	0.000743	0.00389	CbGpPWpGaD
Thalidomide—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00074	0.00188	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000735	0.00187	CcSEcCtD
Thalidomide—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000734	0.00187	CcSEcCtD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—EDN1—focal segmental glomerulosclerosis	0.000733	0.00384	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—TGFB1—focal segmental glomerulosclerosis	0.000732	0.00384	CbGpPWpGaD
Thalidomide—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000728	0.00185	CcSEcCtD
Thalidomide—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000728	0.00185	CcSEcCtD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—focal segmental glomerulosclerosis	0.000722	0.00378	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	0.000712	0.00373	CbGpPWpGaD
Thalidomide—CYP2E1—Vitamin A and Carotenoid Metabolism—LPL—focal segmental glomerulosclerosis	0.000707	0.00371	CbGpPWpGaD
Thalidomide—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000702	0.00179	CcSEcCtD
Thalidomide—TNF—Vitamin B12 Metabolism—SERPINE1—focal segmental glomerulosclerosis	0.000697	0.00365	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000697	0.00177	CcSEcCtD
Thalidomide—TNF—Vitamin B12 Metabolism—ALB—focal segmental glomerulosclerosis	0.000696	0.00365	CbGpPWpGaD
Thalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—focal segmental glomerulosclerosis	0.000692	0.00363	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—focal segmental glomerulosclerosis	0.000679	0.00356	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000678	0.00355	CbGpPWpGaD
Thalidomide—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000677	0.00172	CcSEcCtD
Thalidomide—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000673	0.00171	CcSEcCtD
Thalidomide—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000673	0.00171	CcSEcCtD
Thalidomide—TNF—TGF-beta Receptor Signaling—SERPINE1—focal segmental glomerulosclerosis	0.000666	0.00349	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MYH10—focal segmental glomerulosclerosis	0.000649	0.0034	CbGpPWpGaD
Thalidomide—FGFR2—FGF signaling pathway—MMP9—focal segmental glomerulosclerosis	0.000635	0.00333	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.000635	0.00333	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	0.000632	0.00331	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—COL4A4—focal segmental glomerulosclerosis	0.00063	0.0033	CbGpPWpGaD
Thalidomide—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000628	0.0016	CcSEcCtD
Thalidomide—TNF—TWEAK Signaling Pathway—MMP9—focal segmental glomerulosclerosis	0.000624	0.00327	CbGpPWpGaD
Thalidomide—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000611	0.00155	CcSEcCtD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AGT—focal segmental glomerulosclerosis	0.000608	0.00319	CbGpPWpGaD
Thalidomide—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000603	0.00153	CcSEcCtD
Thalidomide—CYP1A2—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.000601	0.00315	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—CD79A—focal segmental glomerulosclerosis	0.000595	0.00312	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	0.000591	0.0031	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—SPP1—focal segmental glomerulosclerosis	0.000591	0.0031	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—ALB—focal segmental glomerulosclerosis	0.00059	0.00309	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—MMP9—focal segmental glomerulosclerosis	0.000585	0.00306	CbGpPWpGaD
Thalidomide—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000583	0.00148	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—COL4A1—focal segmental glomerulosclerosis	0.000579	0.00303	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—SPP1—focal segmental glomerulosclerosis	0.000577	0.00302	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—SPP1—focal segmental glomerulosclerosis	0.000574	0.00301	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—MMP9—focal segmental glomerulosclerosis	0.00057	0.00299	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—SERPINE1—focal segmental glomerulosclerosis	0.000567	0.00297	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—ALB—focal segmental glomerulosclerosis	0.000566	0.00297	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—CD79A—focal segmental glomerulosclerosis	0.000564	0.00296	CbGpPWpGaD
Thalidomide—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000563	0.00143	CcSEcCtD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TGFB1—focal segmental glomerulosclerosis	0.000552	0.00289	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—TGFB1—focal segmental glomerulosclerosis	0.000544	0.00285	CbGpPWpGaD
Thalidomide—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000542	0.00138	CcSEcCtD
Thalidomide—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000537	0.00137	CcSEcCtD
Thalidomide—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000537	0.00137	CcSEcCtD
Thalidomide—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000534	0.00136	CcSEcCtD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TGFB1—focal segmental glomerulosclerosis	0.000516	0.0027	CbGpPWpGaD
Thalidomide—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000506	0.00129	CcSEcCtD
Thalidomide—TNF—Adipogenesis—LPL—focal segmental glomerulosclerosis	0.000501	0.00263	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	0.000489	0.00256	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—COL4A4—focal segmental glomerulosclerosis	0.00048	0.00251	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000478	0.0025	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MYH9—focal segmental glomerulosclerosis	0.000467	0.00244	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of Telomerase—TGFB1—focal segmental glomerulosclerosis	0.000459	0.0024	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—CTGF—focal segmental glomerulosclerosis	0.000454	0.00238	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—SPP1—focal segmental glomerulosclerosis	0.000452	0.00237	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	0.000451	0.00236	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—SPP1—focal segmental glomerulosclerosis	0.00045	0.00236	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—ALB—focal segmental glomerulosclerosis	0.00045	0.00236	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.00045	0.00236	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—focal segmental glomerulosclerosis	0.000444	0.00233	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—FN1—focal segmental glomerulosclerosis	0.000443	0.00232	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—COL4A1—focal segmental glomerulosclerosis	0.000441	0.00231	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—AGT—focal segmental glomerulosclerosis	0.000429	0.00225	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—NOS2—focal segmental glomerulosclerosis	0.000423	0.00222	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—TGFB1—focal segmental glomerulosclerosis	0.00042	0.0022	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000419	0.0022	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TGFB1—focal segmental glomerulosclerosis	0.000416	0.00218	CbGpPWpGaD
Thalidomide—TNF—Cardiac Hypertrophic Response—TGFB1—focal segmental glomerulosclerosis	0.000414	0.00217	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MYH9—focal segmental glomerulosclerosis	0.000412	0.00216	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	0.000403	0.00211	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MYH9—focal segmental glomerulosclerosis	0.000391	0.00205	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—focal segmental glomerulosclerosis	0.000388	0.00203	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	0.000373	0.00195	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—focal segmental glomerulosclerosis	0.000368	0.00193	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000367	0.00192	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—TGFB1—focal segmental glomerulosclerosis	0.00036	0.00189	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	0.00036	0.00188	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MYH9—focal segmental glomerulosclerosis	0.000355	0.00186	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	0.000351	0.00184	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—ALB—focal segmental glomerulosclerosis	0.00035	0.00184	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000343	0.0018	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—SERPINE1—focal segmental glomerulosclerosis	0.00033	0.00173	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIAS1—focal segmental glomerulosclerosis	0.000324	0.0017	CbGpPWpGaD
Thalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—focal segmental glomerulosclerosis	0.000317	0.00166	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—TGFB1—focal segmental glomerulosclerosis	0.000315	0.00165	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	0.00031	0.00163	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIAS1—focal segmental glomerulosclerosis	0.000307	0.00161	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—focal segmental glomerulosclerosis	0.000306	0.0016	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—focal segmental glomerulosclerosis	0.000295	0.00155	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—MMP9—focal segmental glomerulosclerosis	0.000295	0.00154	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	0.000279	0.00146	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—ALB—focal segmental glomerulosclerosis	0.000278	0.00146	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	0.000274	0.00144	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—MMP9—focal segmental glomerulosclerosis	0.000273	0.00143	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—AGT—focal segmental glomerulosclerosis	0.000269	0.00141	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—focal segmental glomerulosclerosis	0.000263	0.00138	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000262	0.00137	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—NOS2—focal segmental glomerulosclerosis	0.000262	0.00137	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MYH9—focal segmental glomerulosclerosis	0.00024	0.00126	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD79A—focal segmental glomerulosclerosis	0.00024	0.00126	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MYH9—focal segmental glomerulosclerosis	0.000228	0.00119	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD79A—focal segmental glomerulosclerosis	0.000227	0.00119	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—LPL—focal segmental glomerulosclerosis	0.000226	0.00119	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TGFB1—focal segmental glomerulosclerosis	0.000225	0.00118	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.000223	0.00117	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000212	0.00111	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000209	0.0011	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—TGFB1—focal segmental glomerulosclerosis	0.000208	0.00109	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000201	0.00105	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000199	0.00104	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000196	0.00103	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	0.000195	0.00102	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000193	0.00101	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	0.000185	0.000972	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000183	0.000957	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—focal segmental glomerulosclerosis	0.000181	0.000951	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000173	0.000906	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—LPL—focal segmental glomerulosclerosis	0.000172	0.000903	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.00017	0.000889	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MMP9—focal segmental glomerulosclerosis	0.000169	0.000885	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000167	0.000877	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000163	0.000852	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000156	0.000817	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000154	0.000809	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000153	0.000802	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP2—focal segmental glomerulosclerosis	0.000152	0.000794	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD79A—focal segmental glomerulosclerosis	0.000145	0.000762	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TGFB1—focal segmental glomerulosclerosis	0.000139	0.000729	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000138	0.000725	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD79A—focal segmental glomerulosclerosis	0.000138	0.000723	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000137	0.00072	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000122	0.000639	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.00012	0.000628	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.00012	0.000627	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000119	0.000623	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40LG—focal segmental glomerulosclerosis	0.000119	0.000621	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP2—focal segmental glomerulosclerosis	0.000116	0.000605	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	0.000114	0.000597	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000113	0.000595	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000113	0.000594	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000113	0.000591	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40LG—focal segmental glomerulosclerosis	0.000112	0.000589	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000103	0.000541	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	0.000103	0.000537	CbGpPWpGaD
Thalidomide—FGFR2—Disease—LPL—focal segmental glomerulosclerosis	0.000102	0.000534	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.0001	0.000524	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	9.97e-05	0.000523	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	9.52e-05	0.000499	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	9.49e-05	0.000497	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	9.47e-05	0.000496	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	9.39e-05	0.000492	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	9.15e-05	0.000479	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	9.09e-05	0.000477	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	8.83e-05	0.000463	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—LIPC—focal segmental glomerulosclerosis	8.75e-05	0.000459	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—focal segmental glomerulosclerosis	8.68e-05	0.000455	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	8.68e-05	0.000455	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	8.45e-05	0.000443	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	8.14e-05	0.000427	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS2—focal segmental glomerulosclerosis	7.96e-05	0.000417	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	7.87e-05	0.000412	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	7.77e-05	0.000407	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	7.75e-05	0.000406	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CTGF—focal segmental glomerulosclerosis	7.7e-05	0.000404	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.52e-05	0.000394	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	7.36e-05	0.000385	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	7.23e-05	0.000379	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	7.16e-05	0.000375	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.14e-05	0.000374	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	7.13e-05	0.000373	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.1e-05	0.000372	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LIPC—focal segmental glomerulosclerosis	6.95e-05	0.000364	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	6.91e-05	0.000362	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	6.76e-05	0.000354	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SERPINE1—focal segmental glomerulosclerosis	6.7e-05	0.000351	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LIPC—focal segmental glomerulosclerosis	6.54e-05	0.000343	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	6.53e-05	0.000342	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.44e-05	0.000337	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	6.3e-05	0.00033	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	6.25e-05	0.000327	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LIPC—focal segmental glomerulosclerosis	6.17e-05	0.000323	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CTGF—focal segmental glomerulosclerosis	6.12e-05	0.00032	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.11e-05	0.00032	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	5.95e-05	0.000312	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	5.91e-05	0.00031	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CTGF—focal segmental glomerulosclerosis	5.76e-05	0.000302	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	5.75e-05	0.000301	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	5.64e-05	0.000296	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.63e-05	0.000295	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	5.55e-05	0.000291	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CTGF—focal segmental glomerulosclerosis	5.43e-05	0.000284	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	5.39e-05	0.000283	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	5.39e-05	0.000282	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—LPL—focal segmental glomerulosclerosis	5.34e-05	0.00028	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.3e-05	0.000278	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.29e-05	0.000277	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LPL—focal segmental glomerulosclerosis	5.06e-05	0.000265	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	5.05e-05	0.000264	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	5e-05	0.000262	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.95e-05	0.000259	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.69e-05	0.000246	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.61e-05	0.000241	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	4.6e-05	0.000241	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AGT—focal segmental glomerulosclerosis	4.57e-05	0.000239	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	4.54e-05	0.000238	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	4.44e-05	0.000233	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LPL—focal segmental glomerulosclerosis	4.24e-05	0.000222	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—focal segmental glomerulosclerosis	4.23e-05	0.000222	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	4.14e-05	0.000217	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.09e-05	0.000214	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	4.05e-05	0.000212	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LPL—focal segmental glomerulosclerosis	3.99e-05	0.000209	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	3.98e-05	0.000209	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—focal segmental glomerulosclerosis	3.95e-05	0.000207	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	3.93e-05	0.000206	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.79e-05	0.000199	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LPL—focal segmental glomerulosclerosis	3.76e-05	0.000197	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.73e-05	0.000196	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGT—focal segmental glomerulosclerosis	3.63e-05	0.00019	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.6e-05	0.000188	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.54e-05	0.000185	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—focal segmental glomerulosclerosis	3.51e-05	0.000184	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	3.46e-05	0.000181	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGT—focal segmental glomerulosclerosis	3.41e-05	0.000179	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	3.41e-05	0.000179	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—focal segmental glomerulosclerosis	3.33e-05	0.000174	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGT—focal segmental glomerulosclerosis	3.22e-05	0.000169	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.19e-05	0.000167	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.12e-05	0.000164	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	3.08e-05	0.000161	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.96e-05	0.000155	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	2.81e-05	0.000147	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—focal segmental glomerulosclerosis	2.78e-05	0.000146	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	2.63e-05	0.000138	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—focal segmental glomerulosclerosis	2.62e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	2.61e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—focal segmental glomerulosclerosis	2.47e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	2.4e-05	0.000126	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	2.4e-05	0.000126	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—focal segmental glomerulosclerosis	2.1e-05	0.00011	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	2.05e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	2.02e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	1.84e-05	9.66e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	1.57e-05	8.25e-05	CbGpPWpGaD
